Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Stephanie B. Seminara, MD
Study ID
NCT07224490
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Long COVID
  • Neurodegeneration
  • Reproductive Disorder
  • SARS-CoV 2

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Kisspeptin 112-121 — DRUG
    Single bolus of kisspeptin

Study Details

The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.

Key Dates

First listed
Nov 4, 2025
Start date
Mar 10, 2026
Status verified
Jul 2026
Primary completion
May 31, 2030
Completion
May 31, 2030

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Kisspeptin administration
    Single bolus of kisspeptin

Primary Outcome Measure

Difference in mean luteinizing hormone (LH) amplitude between cases and controls [ Time Frame: Day of study visit (one to two hours) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114
Study Coordinator
[email protected]
617-643-2308

Find similar trials in Boston, MA

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Massachusetts General Hospital· Boston, MA

Related Studies